Author: Emma Yasinski

Emma Yasinski

I am a freelance science and medical journalist, fascinated by how the scientific process leads to incredible discoveries, but also can lead to publication bias leaning toward positive findings and minimizing negatives. With a bachelor’s degree in neuroscience from Lafayette College and a Master’s in Science and Medical Journalism from Boston University, I’ve written about clinical trial transparency, organ donation, and basic molecular biology for publications like The Scientist, The Atlantic, Undark.org, Kaiser Health News, and more. At MedShadow, I research and write about the sometimes unexpected ways that medicines can affect us, and what we can do if and when it does.

You have cancer. If that wasn’t terrifying enough, you now face a litany of medical choices, treatments, and drugs. As you try to educate yourself about those options, you also have to weigh the unpredictable nature of their side effects. Unfortunately, the side effects listed on the drug’s label don’t tell us much about what it’s really like to take a drug. A new article published in Undark explains how and why the information patients get on side effects often seems to minimize that challenge that side effects can pose. The article uses cancer drugs as an example and is…

Read More

The primary cause of acne is clogged pores. Your pores can be clogged by bacteria, dead-skin cells or sebum, an oily substance secreted by your skin. The clogs cause redness and inflammation, which can be painful. Some doctors and patients believe that our diets can be the root cause of certain types of acne, but, for the most part, our lifestyles and hygiene are not to blame. Many women experience hormonal acne, which flares up at specific times during their menstrual cycles, or because of hormonal conditions, such as polycystic ovarian syndrome (PCOS), a disorder that affects many women. What…

Read More

A new chemotherapy drug promises to treat some patients with pediatric acute lymphoblastic leukemia (ALL) who have been unable to take the other two other chemo medicines because one can cause allergic reactions and the other is frequently in short supply.  This summer, the Food and Drug Administration (FDA) fast-tracked the approval of Rylaze, a newer version of the chemo drug Erwinaze to treat ALL (leukemia) , made by Jazz Pharmaceuticals, which was previously distributed Erwinaze. The agency approved Rylaze based on an ongoing Phase 2/3 trial of about 102 patients, with an average age of 10.  The rare disease…

Read More